Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$1.14
-2.6%
$1.70
$1.07
▼
$2.58
$303.63M2.321.87 million shs2.35 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.35T0.42.96 million shs3.08 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
0.00%-8.59%-26.88%-48.68%-14.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$1.14
-2.6%
$1.70
$1.07
▼
$2.58
$303.63M2.321.87 million shs2.35 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.35T0.42.96 million shs3.08 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
0.00%-8.59%-26.88%-48.68%-14.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.88
Moderate Buy$10.00765.80% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.00-0.87% Downside

Current Analyst Ratings Breakdown

Latest LLY and AUTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/11/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Reiterated RatingBuy
11/11/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Reiterated RatingBuy
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/3/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/2/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Initiated CoverageBuy
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$75.39M4.08N/AN/A$0.67 per share1.72
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$86.46B15.61$24.98 per share57.42$28.07 per share51.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$287.53M-$0.97N/AN/AN/A-186.37%-263.25%-48.04%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8146.6828.291.7331.90%86.76%22.03%2/3/2027 (Estimated)

Latest LLY and AUTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.21-$0.21N/A-$0.21$39.54 million$41.24 million
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years

Latest LLY and AUTL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
5.25
3.72
3.36
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
752266.34 million197.89 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.75 million939.43 millionOptionable

Recent News About These Companies

M&A News: Eli Lilly (LLY) Buys Calytrix Bio for $1.5 Billion
Pharmaceutical Stocks Worth Watching - November 16th
Healthcare Stocks To Follow Today - November 16th
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$1.14 -0.03 (-2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.02 (-2.11%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,431.12 -12.38 (-0.86%)
Closing price 03:59 PM Eastern
Extended Trading
$1,432.46 +1.34 (+0.09%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.